GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 147
- Registration Number
- NCT05838755
- Locations
- π¬π§
GSK Investigational Site, West Yorkshire, United Kingdom
A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
- Conditions
- Influenza, Human
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1268
- Registration Number
- NCT05823974
- Locations
- πΏπ¦
GSK Investigational Site, Tembisa, South Africa
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
- Conditions
- Herpes Zoster
- Interventions
- Other: Data collection
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2844
- Registration Number
- NCT05811754
Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT05791565
- Locations
- π³π±
GSK Investigational Site, Groningen, Netherlands
Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 27
- Registration Number
- NCT05760261
- Locations
- π¬π§
GSK Investigational Site, Cambridge, United Kingdom
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 292
- Registration Number
- NCT05757102
- Locations
- πΉπ·
GSK Investigational Site, Konyaalti, Turkey
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT05723562
- Locations
- π¬π§
GSK Investigational Site, Sutton, United Kingdom
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT05714839
- Locations
- π¬π§
GSK Investigational Site, Oxford, United Kingdom
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: RSVPreF3 vaccineOther: Control
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3962
- Registration Number
- NCT05705440
- Locations
- πΉπ
GSK Investigational Site, ChiangMai, Thailand
Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4
- Registration Number
- NCT05682326
- Locations
- π°π·
GSK Investigational Site, Yangsan, Korea, Republic of